Edition:
United Kingdom

Calyxt Inc (CLXT.OQ)

CLXT.OQ on NASDAQ Stock Exchange Global Market

6.90USD
20 Aug 2019
Change (% chg)

-- (--)
Prev Close
$6.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
22,456
52-wk High
$19.28
52-wk Low
$6.09

Latest Key Developments (Source: Significant Developments)

Calyxt Files For Mixed Shelf Of Upto $200 Million - SEC Filing
Tuesday, 13 Aug 2019 

Aug 13 (Reuters) - Calyxt Inc ::CALYXT INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.  Full Article

Cellectis Q2 Attributable Consolidated Net Loss Widens To $33 Mln
Tuesday, 6 Aug 2019 

Aug 7 (Reuters) - CELLECTIS SA ::CELLECTIS REPORTED ON TUESDAY FINANCIAL RESULTS FOR SECOND QUARTER AND FIRST SIX MONTHS 2019.Q2 ADJUSTED LOSS PER SHARE $0.65.Q2 LOSS PER SHARE $0.79.AS OF JUNE 30, CELLECTIS, INCLUDING CALYXT HAD $401 MILLION IN CONSOLIDATED CASH, CASH EQUIVALENTS, CURRENT FINANCIAL ASSETS AND RESTRICTED CASH.ON CASH AVAILABLE: $323 MILLION ARE ATTRIBUTABLE TO CELLECTIS ON A STAND-ALONE BASIS.Q2 CONSOLIDATED REVENUES AND OTHER INCOME WERE $3 MILLION VERSUS $8 MILLION YEAR AGO.Q2 CONSOLIDATED R&D EXPENSES WERE $25 MILLION VS $18 MILLION YEAR AGO.Q2 CONSOLIDATED NET LOSS ATTRIBUTABLE TO SHAREHOLDERS OF CELLECTIS WAS $33 MILLION ($0.79/SHARE) VS $7 MILLION YEAR AGO.  Full Article

Calyxt Names Biotech Veteran And Board Of Directors Member Yves Ribeill As Interim CEO
Wednesday, 22 Aug 2018 

Aug 22 (Reuters) - Calyxt Inc ::CALYXT NAMES BIOTECH VETERAN AND BOARD OF DIRECTORS MEMBER DR. YVES J. RIBEILL AS INTERIM CEO.CALYXT NAMES BIOTECH VETERAN AND BOARD OF DIRECTORS MEMBER DR. YVES J. RIBEILL AS INTERIM CEO.CALYXT INC - RIBEILL REPLACES FEDERICO TRIPODI, WHO IS LEAVING COMPANY TO PURSUE OTHER OPPORTUNITIES.CALYXT INC - BOARD HAS APPOINTED YVES RIBEILL AS INTERIM CHIEF EXECUTIVE OFFICER, EFFECTIVE IMMEDIATELY.  Full Article

Calyxt Reports Financial Results For Second Quarter And Half-Year 2018
Wednesday, 1 Aug 2018 

Calyxt Inc ::CALYXT REPORTS FINANCIAL RESULTS FOR SECOND QUARTER AND HALF-YEAR 2018.CALYXT INC - QTRLY LOSS PER SHARE $0.25.  Full Article

Calyxt Announces Upsizing And Pricing Of Follow-On Offering
Friday, 18 May 2018 

May 18 (Reuters) - Calyxt Inc ::CALYXT ANNOUNCES UPSIZING AND PRICING OF FOLLOW-ON OFFERING.CALYXT - PRICE OF FOLLOW-ON PUBLIC OFFERING OF 3.6 MILLION SHARES OF COMMON STOCK LAUNCHED MAY 15 HAS BEEN SET AT $15.00 PER SHARE.CALYXT INC - OFFERING WAS UPSIZED FROM 3.1 MILLION SHARES TO ACCOMMODATE CELLECTIS TO BUY 550,000 SHARES.  Full Article

Calyxt Inc Files For Offering Of Up To 3.05 Mln Shares Of Common Stock
Tuesday, 15 May 2018 

May 15 (Reuters) - Calyxt Inc ::CALYXT INC FILES FOR OFFERING OF UP TO 3.05 MILLION SHARES OF COMMON STOCK - SEC FILING.  Full Article

Bayer Cropscience Agreed To Settle A Lawsuit Brought By Calyxt In Delaware Chancery Court
Tuesday, 15 May 2018 

May 15 (Reuters) - Bayer AG ::CALYXT INC - BAYER CROPSCIENCE LP HAS AGREED TO SETTLE A LAWSUIT BROUGHT BY CALYXT IN DELAWARE CHANCERY COURT.CALYXT - UNDER SETTLEMENT, PARTIES AGREED BAYER WILL DESTROY ANY TECHNOLOGY, RELATED PRODUCT AND CONFIDENTIAL INFORMATION COVERED BY LICENSE AGREEMENT.CALYXT INC - SETTLEMENT CONFIRMS BAYER CROPSCIENCE AND ITS SUBSIDIARIES HAVE NO ACCESS TO CALYXT TECHNOLOGY OR INTELLECTUAL PROPERTY.CALYXT INC- UNDER SETTLEMENT, PARTIES AGREED BAYER WILL PERMANENTLY ABANDON PATENT APPLICATIONS BASED ON OR INCLUDE DATA RELATED TO COVERED TECHNOLOGY.CALYXT INC - SETTLEMENT CONFIRMS BAYER AND ITS SUBSIDIARIES HAVE NO ACCESS TO CALYXT TECHNOLOGY OR INTELLECTUAL PROPERTY.  Full Article

Calyxt reports qtrly ‍basic and diluted loss per share $0.51​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Calyxt Inc :Calyxt reports financial results for third quarter and first nine months of 2017.Calyxt Inc - ‍Expect current cash position to be sufficient to fund operations through mid-2019​.Calyxt Inc - Qtrly ‍basic and diluted loss per share $0.51​.Q3 earnings per share view $-0.14 -- Thomson Reuters I/B/E/S.  Full Article